Method for treating hyperhidrosis with dexmecamylamine
View Patent ↗The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of hyperhidrosis.
1. A method of treating hyperhidrosis, the method comprising the administration of a therapeutically effective amount of dexmecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, to a subject with hyperhidrosis, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is administered in an amount from about 0.1 mg to about 4.0 mg.
2. A method of treating hyperhidrosis, the method comprising the oral administration of dexmecamylamine or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg to about 2.0 mg once daily, substantially free of exo-R-mecamylamine, to a subject with hyperhidrosis.
3. The method according to claim 2 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 0.2 mg once daily.
4. The method according to claim 2 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 0.5 mg once daily.
5. The method according to claim 2 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 1.0 mg once daily.
6. The method according to claim 2 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 2.0 mg once daily.
7. The method according to claim 2 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in tablet form.
8. A method of treating hyperhidrosis comprising the oral administration of dexmecamylamine or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg to about 2.0 mg once daily, substantially free of exo-R-mecamylamine, to a subject with hyperhidrosis, wherein the administration of dexmecamylamine is sufficient to affect sweating in a patient in at least one location with an Hyperhidrosis Disease Severity Scale change of >1.
9. The method according to claim 8 , wherein the administration of dexmecamylamine is sufficient to affect sweating in a patient in at least two locations with an HDSS change of >0.5, in each location.
10. The method according to claim 8 , wherein the location is selected from axillary, palmoplantar, face/scalp, or generalized.
11. The method according to claim 2 , wherein the hyperhidrosis is primary hyperhidrosis.
12. The method according to claim 2 , wherein the subject is a human.
13. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is administered once daily.
14. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is administered more than once daily.
15. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 1.0 mg.
16. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 2.0 mg.
17. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 4.0 mg.
18. The method according to claim 1 , wherein the hyperhidrosis is primary hyperhidrosis.
19. The method according to claim 1 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in tablet form.